This Article Full Text Full Text (PDF) All Versions of this Article: 44/2/146    most recent 01.HYP.0000130174.70055.cav1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Julius, S. Search for Related Content PubMed PubMed Citation Articles by Julius, S. Related Collections Clinical Studies Epidemiology Other hypertension Primary prevention

(Hypertension. 2004;44:146.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Trial of Preventing Hypertension

Design and 2-Year Progress Report

Stevo Julius; Shawna Nesbitt; Brent Egan; Niko Kaciroti; M. Anthony Schork; Melissa Grozinski; Eric Michelson for the TROPHY study group

From the Division of Cardiovascular Medicine (S.J., N.K.), University of Michigan Medical Center, Ann Arbor; the Emeritus Department of Biostatistics School of Public Health (M.A.S), University of Michigan, Ann Arbor; the Department of Internal Medicine (S.N.), Division of Hypertension, University of Texas Southwestern Medical Center at Dallas; the Division of Clinical Pharmacology (B.E.), Medical University of South Carolina, Charleston; and AstraZeneca, LP (M.G., E.M.), Wilmington, Del.

Correspondence to Stevo Julius, MD, MD (Hon), ScD, Professor of Internal Medicine and Physiology, Fredrick G.L. Huetwell Professor of Hypertension, University of Michigan Medical Center 3918 TC, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0500. E-mail sjulius{at}umich.edu

The TRial Of Preventing HYpertension (TROPHY) study is an investigator-initiated trial to examine whether early pharmacological treatment in subjects with "high-normal" blood pressure (BP) might prevent or delay the development of clinical hypertension. This is a 4-year, multicenter, randomized, double-blind study in untreated subjects aged 30 to 65 years with entry BPs of 130 to 139/89 or 139/85 to 89. The participants were randomized either to placebo or to a fixed (16 mg once daily) dose of candesartan cilexetil (candesartan). After 2 years, the candesartan group was switched to placebo, and the placebo group continued taking placebo. The main outcome measure was the development of clinical (treatment-requiring) hypertension assessed by an automated (blinded) BP measurement device. We randomized 809 subjects (59% males, average age 49.0±SD 8.1 years) in 71 study centers in the United States. The entry BP was 134±4.3/84.8±3.9 mm Hg. During the first 2 years, 187 subjects (23%) developed clinical hypertension. All have been given antihypertensive treatment, and 170 continue to be followed in study centers. The study dropout rate is 14.8% (120 subjects). The hypertension rates are higher than anticipated, whereas the rates of dropout are within the sample size projections; thus, the study will have sufficient power to evaluate its hypotheses. In this article, we describe baseline characteristics of TROPHY subjects and discuss novel analytical issues and statistical approaches to evaluate the findings in this trial of primary prevention of hypertension.

Key Words: hypertension, detection and control • blood pressure • receptors, angiotensin • angiotensin antagonist

This article has been cited by other articles:

				B. M. Egan, S. D. Nesbitt, and S. Julius Review: Prehypertension: should we be treating with pharmacologic therapy? Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 305 - 314. [Abstract] [PDF]

				C. Y. Shim, J.-W. Ha, S. Park, E.-Y. Choi, D. Choi, S.-J. Rim, and N. Chung Exaggerated Blood Pressure Response to Exercise Is Associated With Augmented Rise of Angiotensin II During Exercise J. Am. Coll. Cardiol., July 22, 2008; 52(4): 287 - 292. [Abstract] [Full Text] [PDF]

				S. Julius, S. D. Nesbitt, B. M. Egan, M. A. Weber, E. L. Michelson, N. Kaciroti, H. R. Black, R. H. Grimm Jr., F. H. Messerli, S. Oparil, et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker N. Engl. J. Med., April 20, 2006; 354(16): 1685 - 1697. [Abstract] [Full Text] [PDF]

				N. M. Kaplan Treatment of Hypertension: Remaining Issues After the Anglo-Scandinavian Cardiac Outcomes Trial Hypertension, January 1, 2006; 47(1): 10 - 13. [Full Text] [PDF]

				N. M. Kaplan An Updated Meta-Analysis With a Few Surprises Hypertension, August 1, 2005; 46(2): 257 - 258. [Full Text] [PDF]

				N. M. Kaplan Trial of Preventing Hypertension (TROPHY): Design and 2-Year Progress Report Hypertension, August 1, 2004; 44(2): 125 - 126. [Full Text] [PDF]